LIBRAX Drug Patent Profile

« Back to Dashboard

Which patents cover Librax, and what generic alternatives are available?

Librax is a drug marketed by Bausch and is included in one NDA.

The generic ingredient in LIBRAX is chlordiazepoxide hydrochloride; clidinium bromide. There is one drug master file entry for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the chlordiazepoxide hydrochloride; clidinium bromide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Librax

A generic version of LIBRAX was approved as chlordiazepoxide hydrochloride; clidinium bromide by NUVO PHARMS INC on July 7^th, 2020.

Summary for LIBRAX

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	4
Drug Prices:	Drug price information for LIBRAX
What excipients (inactive ingredients) are in LIBRAX?	LIBRAX excipients list
DailyMed Link:	LIBRAX at DailyMed

See drug prices for LIBRAX

Pharmacology for LIBRAX

Drug Class	Anticholinergic Benzodiazepine
Mechanism of Action	Cholinergic Antagonists
Physiological Effect	Decreased Parasympathetic Acetylcholine Activity Digestive/GI System Activity Alteration GI Motility Alteration

US Patents and Regulatory Information for LIBRAX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bausch	LIBRAX	chlordiazepoxide hydrochloride; clidinium bromide	CAPSULE;ORAL	012750-001	Approved Prior to Jan 1, 1982	AB	RX	Yes	Yes

Expired US Patents for LIBRAX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bausch	LIBRAX	chlordiazepoxide hydrochloride; clidinium bromide	CAPSULE;ORAL	012750-001	Approved Prior to Jan 1, 1982

Librax Market Dynamics and Financial Trajectory: Sales, Competition, Exclusivity, and Commercial Outlook

Last updated: October 31, 2026

Librax is a legacy fixed-dose combination of chlordiazepoxide hydrochloride 5 mg and clidinium bromide 2.5 mg. Its commercial position is defined by generic competition, limited clinical differentiation, controlled-substance regulation for chlordiazepoxide, and the absence of a meaningful modern patent moat. Librax is not a material growth product for its manufacturer, and standalone revenue is not publicly disclosed. Its financial trajectory is best characterized as a mature, low-growth prescription product with residual brand value and fragmented generic competition.

What is Librax and who markets it?

Librax combines:

Component	Pharmacologic role	Regulatory relevance
Chlordiazepoxide hydrochloride	Benzodiazepine anxiolytic	Schedule IV controlled substance in the United States
Clidinium bromide	Anticholinergic gastrointestinal agent	Non-controlled active ingredient
Dosage form	Oral capsule	Immediate-release combination product
Standard strength	5 mg chlordiazepoxide / 2.5 mg clidinium bromide	Original branded presentation

The original U.S. product was developed for gastrointestinal disorders involving anxiety, visceral spasm, and excessive gastrointestinal motility. Its historical indications included irritable bowel syndrome and peptic-ulcer-related gastrointestinal symptoms. Modern treatment guidelines have shifted toward non-benzodiazepine approaches, limiting Librax’s growth potential.

Librax has been associated with Valeant Pharmaceuticals International and later Bausch Health Companies. Product labeling identifies Valeant Pharmaceuticals North America LLC as the applicant or marketer for the U.S. branded product in relevant FDA labeling records. The brand’s manufacturing and distribution status has changed over time, and retail availability can vary by pharmacy and wholesaler.

What is the FDA regulatory status of Librax?

Librax was approved decades before the modern new-drug approval framework was fully established. FDA labeling identifies the product under NDA 012750. The product is an approved prescription oral capsule containing a benzodiazepine and an anticholinergic agent.[1]

The principal regulatory constraints are:

• Chlordiazepoxide is a Schedule IV controlled substance.
• The product carries benzodiazepine class warnings, including risks of abuse, misuse, addiction, dependence, and withdrawal.
• Concomitant use with opioids can cause profound sedation, respiratory depression, coma, and death.
• Elderly patients face increased risks from sedation, confusion, falls, and anticholinergic effects.
• Long-term use is clinically constrained by dependence and tolerability concerns.

The FDA’s 2020 class-wide benzodiazepine labeling update required boxed-warning language addressing abuse, misuse, addiction, physical dependence, and withdrawal reactions.[2] That update increases prescribing friction for Librax and other chlordiazepoxide-containing products.

What is the Orange Book status of Librax?

Librax’s commercial protection does not depend on a current blockbuster patent estate. The product is an old small-molecule combination, and its original composition, formulation, and therapeutic-use patents have long passed their ordinary patent terms.

The relevant exclusivity position is:

Protection category	Librax position
New chemical entity exclusivity	Expired
Original composition patent protection	Expired
Original formulation protection	Expired or commercially immaterial
Pediatric exclusivity	No material current protection identified
Orphan-drug exclusivity	None
Current commercial moat	Brand recognition, prescriber familiarity, supply continuity
Paragraph IV exposure	Limited practical relevance because core protection is expired

The FDA Orange Book is the primary source for current patent listings, therapeutic-equivalence evaluations, and approved multisource status.[3] Librax’s economic exposure is therefore driven by generic availability and controlled-substance compliance rather than by patent expiration timing.

When did Librax lose exclusivity?

Librax lost meaningful market exclusivity many years ago. The product belongs to the pre-1984 era of pharmaceutical regulation, before the Hatch-Waxman framework created the modern five-year new-chemical-entity exclusivity period.

The commercial consequences were significant:

1. Generic manufacturers could pursue approval without relying on a current branded patent moat.
2. Pharmacy substitution became possible where FDA-rated therapeutically equivalent products were available.
3. Pricing shifted from branded-product economics toward low-volume generic economics.
4. Marketing shifted from broad physician promotion to distribution, contract manufacturing, and pharmacy availability.

Because Librax is a combination of older active ingredients, its commercial life has depended on continued demand rather than regulatory exclusivity.

How many patents cover Librax?

No active, commercially significant patent portfolio is generally associated with the core Librax capsule. The original drug substance patents for chlordiazepoxide and clidinium bromide are expired. Any surviving patents covering manufacturing processes, packaging, or narrow formulations would have limited relevance unless listed for the marketed product and enforceable against a competing product.

A patent review should distinguish among:

• Patents covering chlordiazepoxide itself.
• Patents covering clidinium bromide itself.
• Patents covering the fixed-dose combination.
• Patents covering capsule excipients or release characteristics.
• Patents covering methods of treating gastrointestinal disorders.
• Patents listed in the FDA Orange Book.

For Librax, the commercially decisive category is the approved product’s active-ingredient combination. That protection is old and does not support premium pricing.

Are there generic Librax products?

Yes. The generic product is typically described as chlordiazepoxide hydrochloride and clidinium bromide capsules. Generic manufacturers and repackagers have supplied the combination at different points, but market participation can fluctuate because the product is relatively low volume.

Generic availability does not necessarily guarantee stable supply. Legacy combination products can face:

• Low manufacturing margins.
• Limited active pharmaceutical ingredient suppliers.
• Controlled-substance quota requirements for chlordiazepoxide.
• Small production runs.
• Wholesaler delisting or inventory rationalization.
• Periodic manufacturer discontinuations.
• Pharmacy-level substitution and reimbursement pressure.

The market is therefore mature but not necessarily deep. A product can have generic competition while still experiencing intermittent availability.

Which companies compete with Librax?

Librax competes with both direct generic equivalents and clinically substitutable therapies.

Direct product competitors

The direct competitors are manufacturers and repackagers of chlordiazepoxide hydrochloride and clidinium bromide capsules. The identity of active suppliers may change over time because the product has limited volume and is not a strategic growth asset for most large pharmaceutical companies.

Therapeutic competitors

Librax also competes with:

Therapeutic segment	Examples	Competitive effect
Antispasmodics	Dicyclomine, hyoscyamine	Often used without a benzodiazepine
IBS therapies	Linaclotide, plecanatide, rifaximin, lubiprostone	Target specific IBS subtypes
Acid-suppression therapies	Proton-pump inhibitors, H2 blockers	Address upper gastrointestinal symptoms
Non-drug approaches	Dietary modification, behavioral therapy	Reduce reliance on sedating medicines
Anxiolytics	Non-benzodiazepine agents, antidepressants	Address anxiety without combining it with an anticholinergic

Dicyclomine and hyoscyamine are particularly relevant substitutes for the gastrointestinal antispasmodic component. Modern IBS treatment increasingly uses subtype-specific agents rather than a benzodiazepine-anticholinergic combination.

What is the market size for Librax?

Standalone Librax revenue is not publicly reported by Bausch Health or other companies in a consistent, product-level series. Public company filings generally aggregate products into broader categories and do not isolate Librax sales.

The product’s likely economic profile is:

• Low annual revenue relative to Bausch Health’s principal brands.
• Limited or no meaningful contribution to consolidated growth.
• Higher unit pricing for the brand but lower volume than large chronic-care drugs.
• Generic price erosion where equivalent products are available.
• Revenue volatility caused by supply and channel changes rather than prescription expansion.

Librax is unlikely to have material exposure to the large IBS drug market because its use is narrower, older, and constrained by benzodiazepine safety considerations. Market value is better assessed through prescription volume, average realized price, channel availability, and generic-versus-branded share than through total disease-market size.

How has Librax’s financial trajectory changed?

Librax’s financial trajectory follows the standard pattern for an older branded prescription combination:

Period	Commercial characteristics
Initial commercialization	Differentiated combination product with limited direct competition
Post-generic period	Volume retained through physician familiarity and patient continuity
Mature branded phase	Prescription decline and price pressure
Current phase	Residual brand demand, generic substitution, supply-driven volatility

The principal revenue risks are structural:

1. Generic substitution reduces branded volume.
2. Benzodiazepine warnings discourage new prescribing.
3. Anticholinergic risks reduce use in older adults.
4. Gastroenterology treatment has moved toward targeted non-benzodiazepine medicines.
5. Payers may prefer low-cost generics or alternative antispasmodics.
6. Controlled-substance distribution requirements increase operating complexity.

The product may retain value in a narrow patient population with historical response, but that value does not translate into a durable growth trajectory.

What formulation patents protect Librax?

No modern formulation feature appears to provide a material competitive barrier for the standard immediate-release capsule. The product is not a biologic, depot formulation, transdermal system, or complex delivery technology.

Potential formulation issues include:

• Capsule composition.
• Dissolution and release characteristics.
• Stability of the two active ingredients.
• Packaging and storage.
• Manufacturing controls for a controlled-substance combination.

These factors can create regulatory or manufacturing hurdles without creating meaningful patent exclusivity. A generic manufacturer may still need to demonstrate pharmaceutical equivalence, bioequivalence, content uniformity, and appropriate controls for chlordiazepoxide.

What manufacturing and intellectual-property barriers affect Librax?

Manufacturing barriers are more important than patent barriers.

Controlled-substance compliance

Chlordiazepoxide is subject to Drug Enforcement Administration controls. Manufacturers must manage:

• Production quotas.
• Secure storage.
• Inventory reconciliation.
• Recordkeeping.
• Distribution controls.
• Theft and diversion prevention.

Combination-product manufacturing

The product requires reliable blending and encapsulation of two active ingredients with different physical and pharmacologic properties. Batch failures, low demand, and limited supplier networks can make the product unattractive to manufacturers.

Active ingredient sourcing

The market depends on suppliers of chlordiazepoxide hydrochloride and clidinium bromide that meet FDA current good manufacturing practice requirements. A disruption involving either ingredient can interrupt finished-dose production.

These barriers can support short-term price increases or supply scarcity, but they do not create a durable proprietary moat.

What patent litigation and Paragraph IV challenges affect Librax?

No major current patent litigation involving Librax is central to its commercial outlook. The reason is straightforward: the core product is old, and its principal exclusivity period expired long ago.

Paragraph IV litigation is generally associated with a generic applicant challenging an unexpired Orange Book-listed patent. For Librax, the greater commercial risk is not a fresh Paragraph IV event but the opposite: generic competition already exists or can enter without confronting a meaningful patent barrier.

Any future litigation would more likely involve:

• Manufacturing or supply contracts.
• Trademark rights.
• Controlled-substance distribution.
• Product liability.
• FDA enforcement.
• Generic equivalence or labeling disputes.

What is the biosimilar risk for Librax?

Librax has no biosimilar risk because it is a conventional small-molecule drug, not a biologic. The relevant competitive category is generic substitution under the abbreviated new drug application pathway.

This distinction matters commercially:

Issue	Librax
Biosimilar pathway	Not applicable
Generic pathway	Applicable
Interchangeability	Determined through FDA therapeutic-equivalence standards
Main competitive pressure	Generic price and pharmacy substitution
Patent complexity	Low relative to biologics

What generic launch scenarios exist for Librax?

Three scenarios are commercially plausible.

Continued low-volume generic supply

Several suppliers remain active, but none invests heavily in promotion. Prices remain low, and availability is adequate except for periodic wholesaler disruptions.

Single-source or limited-source supply

Manufacturers exit because of low margins or compliance costs. A remaining supplier gains temporary pricing power, but the market stays small and vulnerable to shortages.

Brand persistence in a niche

The branded product remains available for patients and physicians who prefer the original product or encounter limited generic supply. Brand pricing can remain high, but volume continues to decline.

The third scenario can produce occasional revenue resilience without reversing the long-term trend.

How does Librax compare with competing gastrointestinal drugs?

Attribute	Librax	Dicyclomine	Linaclotide	Rifaximin
Product type	Benzodiazepine-anticholinergic combination	Anticholinergic antispasmodic	Guanylate cyclase-C agonist	Antibiotic
Main use	Gastrointestinal spasm with associated anxiety	IBS-related spasm	IBS with constipation and related disorders	IBS with diarrhea and other indications
Controlled substance	Yes, due to chlordiazepoxide	No	No	No
Patent position	Expired legacy product	Generic	Modern branded patent estate	Branded patent and regulatory protection
Growth outlook	Declining or stable niche	Mature generic	Specialty growth potential	Specialty and label-dependent
Safety constraints	Dependence, sedation, anticholinergic effects	Anticholinergic effects	Diarrhea and dehydration risks	Antibiotic stewardship and recurrence concerns

Librax is disadvantaged against newer products in clinical targeting, regulatory positioning, and commercial support. It retains a role where combined anxiolytic and antispasmodic effects are considered useful, but that niche is narrow.

What licensing deals affect Librax?

No major recent licensing transaction has made Librax a strategic growth asset. Its commercial history has involved product ownership, distribution, and portfolio transfers associated with broader pharmaceutical transactions rather than a stand-alone innovation partnership.

The absence of a significant licensing narrative is itself commercially relevant. Librax does not appear to be positioned as a platform product, a specialty-care growth driver, or a product with meaningful lifecycle-management potential.

What is the generic entry risk for Librax?

Generic entry risk is high in the structural sense because the product has no meaningful remaining core exclusivity. The more important question is the impact of additional suppliers.

Additional generic entry would likely cause:

• Lower average selling prices.
• Greater pharmacy substitution.
• Reduced branded prescription volume.
• More procurement pressure from wholesalers and pharmacy benefit managers.
• Less incentive for branded promotion.

The countervailing factor is limited market size. A small market may not attract many new entrants, allowing temporary supply concentration. That dynamic can moderate price erosion without restoring brand exclusivity.

What is the geographic coverage of Librax?

Librax’s strongest historical commercial recognition is in the United States. Availability in other jurisdictions varies because chlordiazepoxide is controlled or prescription-restricted in many countries, while the product’s clinical positioning is not universally accepted.

International commercial constraints include:

• Country-specific controlled-substance rules.
• Different treatment standards for IBS and functional gastrointestinal disorders.
• National reimbursement controls.
• Local generic competition.
• Product registration and renewal requirements.
• Restrictions on benzodiazepine prescribing.

The United States remains the most relevant jurisdiction for analyzing Librax’s brand, Orange Book, generic, and controlled-substance exposure.

How strong is the Librax patent estate?

Librax’s patent estate is weak from a present-day commercial perspective. Its principal strengths are legacy brand recognition, historical prescribing, and possible supply scarcity. Its weaknesses are expired exclusivity, generic substitutability, limited clinical differentiation, and safety restrictions.

Factor	Assessment
Core composition patent	Weak or expired
Formulation protection	No material current moat
Method-of-use protection	No material current moat
FDA exclusivity	Expired
Generic exposure	High
Biosimilar exposure	None
Manufacturing complexity	Moderate
Brand recognition	Residual but meaningful in a narrow niche
Revenue growth potential	Low

Key Takeaways

• Librax is a mature fixed-dose combination of chlordiazepoxide and clidinium bromide.
• Its original exclusivity has expired, and no material modern patent moat supports the brand.
• The relevant competitive threat is generic substitution, not biosimilar competition.
• Standalone Librax revenue is not publicly disclosed and is unlikely to be material to Bausch Health’s consolidated financial performance.
• Benzodiazepine warnings, controlled-substance compliance, dependence risk, and anticholinergic effects constrain new prescribing.
• Generic supply may remain fragmented because the product has low volume and requires controlled-substance manufacturing controls.
• The product’s most plausible financial trajectory is stable-to-declining niche revenue, with volatility driven by supply and channel changes.
• Manufacturing and distribution barriers are more important than intellectual-property barriers.
• Librax is commercially weaker than newer IBS products with active patent estates and targeted indications.

FAQs About Librax Market Dynamics

Is Librax still commercially available?

Availability varies by manufacturer, wholesaler, pharmacy, and jurisdiction. The branded product and generic chlordiazepoxide/clidinium capsules may not be continuously stocked in every market.

Is Librax a controlled substance?

Yes. Chlordiazepoxide is a Schedule IV benzodiazepine in the United States, making Librax subject to controlled-substance prescribing and distribution requirements.

Can generic Librax be substituted automatically?

Substitution depends on the specific generic product, FDA therapeutic-equivalence rating, state pharmacy law, and the prescriber’s instructions. Pharmacists generally assess substitution under applicable state and federal rules.

Does Librax have a patent that blocks generic manufacturers?

The original product’s meaningful exclusivity has expired. Any current patent analysis must focus on specific Orange Book listings, but Librax does not have the profile of a product protected by a current blocking patent estate.

Is Librax a growth product for Bausch Health?

Librax is not generally identified as a major growth driver in Bausch Health’s public portfolio disclosures. Its economics are consistent with a mature, low-volume legacy product rather than a strategic expansion asset.

References

1. U.S. Food and Drug Administration. (n.d.). Librax: Chlordiazepoxide hydrochloride and clidinium bromide capsule prescribing information.
2. U.S. Food and Drug Administration. (2020). FDA requiring Boxed Warning updated to improve safe use of benzodiazepine drug class.
3. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book.
4. U.S. Drug Enforcement Administration. (2024). Controlled substances alphabetical order.
5. Bausch Health Companies Inc. (2024). Annual report and Form 10-K.